The CASSISS Randomized Clinical Trial

Peng Gao, MD; Tao Wang, MD; Daming Wang, MD; David S. Liebeskind, MD; Huaizhang Shi, MD; Tianxiao Li, MD; Zhenwei Zhao, MD; Yiling Cai, MD; Wei Wu, MD; Weiwen He, MD; Jia Yu, MD; Bingjie Zheng, MD; Haibo Wang, PhD; Yangfeng Wu, PhD; Adam A. Dmytriw, MD; Timo Krings, MD; Colin P. Derdeyn, MD; Liqun Jiao, MD; for the CASSISS Trial Investigators

page 529

page 543

CE Prior randomized trials have generally shown harm or no benefit of stenting added to medical therapy for patients with symptomatic severe intracranial atherosclerotic stenosis, but it remains uncertain as to whether refined patient selection and more experienced surgeons might result in improved outcomes.

E To compare stenting plus medical therapy vs medical therapy alone in patients with symptomatic severe intracranial atherosclerotic stenosis.

D Multicenter, open-label, randomized, outcome assessor–blinded trial conducted at 8 centers in China. A total of 380 patients with transient ischemic attack or nondisabling, nonperforator (defined as nonbrainstem or non–basal ganglia end artery) territory ischemic stroke attributed to severe intracranial stenosis (70%-99%) and beyond a duration of 3 weeks from the latest ischemic symptom onset were recruited between March 5, 2014, and November 10, 2016, and followed up for 3 years (final follow-up: November 10, 2019).

E Medical therapy plus stenting (n = 176) or medical therapy alone (n = 182). Medical therapy included dual-antiplatelet therapy for 90 days (single antiplatelet therapy thereafter) and stroke risk factor control.

E The primary outcome was a composite of stroke or death within 30 days or stroke in the qualifying artery territory beyond 30 days through 1 year. There were 5 secondary outcomes, including stroke in the qualifying artery territory at 2 years and 3 years as well as mortality at 3 years.

E Among 380 patients who were randomized, 358 were confirmed eligible (mean age, 56.3 years; 263 male [73.5%]) and 343 (95.8%) completed the trial. For the stenting plus medical therapy group vs medical therapy alone, no significant difference was found for the primary outcome of risk of stroke or death (8.0% [14/176] vs 7.2% [13/181]; difference, 0.4% [95% CI, −5.0% to 5.9%]; hazard ratio, 1.10 [95% CI, 0.52-2.35]; = .82). Of the 5 prespecified secondary end points, none showed a significant difference including stroke in the qualifying artery territory at 2 years (9.9% [17/171] vs 9.0% [16/178]; difference, 0.7% [95% CI, −5.4% to 6.7%]; hazard ratio, 1.10 [95% CI, 0.56-2.16]; = .80) and 3 years (11.3% [19/168] vs 11.2% [19/170]; difference, −0.2% [95% CI, −7.0% to 6.5%]; hazard ratio, 1.00 [95% CI, 0.53-1.90]; > .99). Mortality at 3 years was 4.4% (7/160) in the stenting plus medical therapy group vs 1.3% (2/159) in the medical therapy alone group (difference, 3.2% [95% CI, −0.5% to 6.9%]; hazard ratio, 3.75 [95% CI, 0.77-18.13]; = .08).

C Among patients with transient ischemic attack or ischemic stroke due to symptomatic severe intracranial atherosclerotic stenosis, the addition of percutaneous transluminal angioplasty and stenting to medical therapy, compared with medical therapy alone, resulted in no significant difference in the risk of stroke or death within 30 days or stroke in the qualifying artery territory beyond 30 days through 1 year. The findings do not support the addition of percutaneous transluminal angioplasty and stenting to medical therapy for the treatment of patients with symptomatic severe intracranial atherosclerotic stenosis.

T ClinicalTrials.gov Identifier: NCT01763320

A A. 2022;328(6):534-542. doi:10.1001/jama.2022.12000

A A : Author affiliations are listed at the end of this article.

: The CASSISS Trial Investigators are listed in Supplement 4.

C A : Liqun Jiao, MD, Department of Neurosurgery and Interventional Neuroradiology, Xuanwu Hospital, China International Neuroscience Institute, Capital Medical University, National Center for Neurological Disorders, 45 Changchun St, Beijing 100053, China (liqunjiao@sina.cn).

1. -
( )



[a] Primary outcome was assessed up to 1 year.

[b] Time points at which some secondary outcomes were assessed.

. A - (h h h)
h SAS , . (SAS I). h PPS .

Results

F M h , , N , , , . A - Th h FAS
h ( ) (,) (**Figure 1**). O h , , (h h (**Table 1**). Th (SD)
h h) - . (.) , . % . Th
h . Th . A
( ) h , (. %) h
(. %), h (. %), h (. %) (T). Th h -
(. %). Th (T ;
(h h h h) T S). Th
h FAS . A (T F S).
(. %) h .
S h h P h h -
. A h h C -
, h . Th , h h
h h h - h h
h h , (: . % / : . % / ,
. % % CI, . % . % HR, . % CI, . - .

1.

Characteristic	No. (%) Percutaneous transluminal angioplasty and stenting group (n = 176)	Medical therapy alone group (n = 182)
Age, mean (SD), y	56.7 (9.4)	55.9 (9.8)
Sex		
Male	128 (72.7)	135 (74.2)
Female	48 (27.3)	47 (25.8)
Ethnicity[a]		
Han	172 (97.7)	179 (98.4)
Non-Han	4 (2.3)	3 (1.6)
Medical history[b]		
Hypertension	117 (66.5)	125 (68.7)
Diabetes	57 (32.4)	44 (24.2)
Coronary artery disease	19 (10.8)	19 (10.4)
Lipid disorder	18 (10.2)	21 (11.5)
Peripheral artery disease	0 (0.0)	1 (0.5)
Received antiplatelet therapy prior to latest qualifying event	49 (27.8)	48 (26.4)
Received statin therapy prior to latest qualifying event	19 (10.8)	20 (11.0)
Alcohol history		
Former	25 (14.2)	22 (12.1)
Current	30 (17.0)	32 (17.6)
Smoking history		
Former	39 (22.2)	38 (20.9)
Current	41 (23.3)	50 (27.5)
Qualifying event		
TIA[c]	87 (49.4)	77 (42.3)
Stroke	89 (50.6)	105 (57.7)
Artery-to-artery embolism	57 (64.0)	58 (55.2)
Isolated hemodynamic compromise[d]	18 (20.2)	22 (21.0)
Mixed mechanism	14 (15.7)	25 (23.8)
Time from latest ischemic event to randomization, median (IQR), d	34.5 (27.0-65.5)	36.0 (28.0-68.0)
TIA	33.0 (25.0-52.0)	33.0 (28.0-57.0)
Stroke	38.0 (27.0-75.0)	40.0 (29.0-72.0)
Symptomatic qualifying artery		
Middle cerebral artery (M1)	65 (36.9)	79 (43.4)
Basilar artery	50 (28.4)	52 (28.6)
Intracranial vertebral artery	46 (26.1)	34 (18.7)
Intracranial internal carotid artery	15 (8.5)	17 (9.3)
Stenosis of symptomatic qualifying artery[e]		
% Stenosis, median (IQR)	78.5 (74.1-82.6)	76.6 (73.2-80.9)
Distribution, % stenosis		
70-79	105 (59.7)	130 (71.4)
80-89	65 (36.9)	46 (25.3)
90-99	6 (3.4)	6 (3.3)

( )

1. ( )

Characteristic	No. (%) Percutaneous transluminal angioplasty and stenting group (n = 176)	Medical therapy alone group (n = 182)
NIHSS score, median (IQR)[f]	0.0 (0.0-1.0)	0.0 (0.0-0.0)
mRS score, median (IQR)[g]	0.0 (0.0-1.0)	0.0 (0.0-1.0)

Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack.

[a] Ethnicity was self-reported.

[b] Medical history was collected at the baseline visit, based on a combination of self-reports from patients, medicated conditions, and laboratory results.

[c] TIA was a clinical diagnosis without imaging.

[d] Isolated hemodynamic compromise refers to strokes with an arterial border zone or "watershed" pattern.

[e] Stenosis was quantified on the basis of a reading of the angiogram by the site interventionist on the criteria of the WASID trial.[18]

[f] NIHSS score ranges from 0 to 42, with higher scores indicating worse neurologic deficits.

[g] mRS score ranges from 0 to 6, with higher scores indicating worse function deficits (0 indicates no deficit and 6 indicates death).

2. -



The primary outcome was stroke or death within 30 days after enrollment or stroke in the qualifying artery territory beyond 30 days through 1 year. One patient lost to follow-up within 1 year in the control group was treated as censored data. All other patients were followed up to event or 1 year. = .82 for log-rank testing between the stenting and medical therapy alone groups with center as stratification factor.

P = .) (**Figure 2** **Table 2**). Th - (. % / . % / HR, . % CI, . - . ; *P* = .) (F S).

N h h h (. % / h . % / h h ; , .% % CI, . % .% HR, . % CI, . - . ; *P* = .), - h h h (. % / . % / ;

2.

	No./total (%)				
	Percutaneous transluminal angioplasty and stenting group (n = 176)	Medical therapy alone group (n = 181)[a]	Incidence difference, % (95% CI)[b]	Hazard ratio (95% CI)[b]	*P* value[c]
Components of the primary outcome	14/176 (8.0)	13/181 (7.2)	0.4 (−5.0 to 5.9)	1.10 (0.52 to 2.35)	.82
Stroke or death within 30 d after enrollment[d]	9/176 (5.1)[e]	4/181 (2.2)[f]			
Stroke in territory of qualifying artery beyond 30 d through 1 y[d]	5/176 (2.8)	9/181 (5.0)			
Secondary outcomes					
Stroke in the same territory within 2 y	17/171 (9.9)[g]	16/178 (9.0)[h]	0.7 (−5.4 to 6.7)	1.10 (0.56 to 2.16)	.80
Stroke in the same territory within 3 y	19/168 (11.3)[i]	19/170 (11.2)[j]	−0.2 (−7.0 to 6.5)	1.00 (0.53 to 1.90)	>.99
Disabling stroke or death within 3 y	19/168 (11.3)[k]	15/166 (9.0)[l]	2.0 (−4.6 to 8.6)	1.28 (0.65 to 2.52)	.49
Any stroke, TIA, cardiovascular events related to stenting or medical therapy within 3 y	24/169 (14.2)[m]	31/172 (18.0)[n]	−4.1 (−12.0 to 3.7)	0.76 (0.45 to 1.30)	.31
Death within 3 y	7/160 (4.4)[o,p]	2/159 (1.3)[q,r]	3.2 (−0.5 to 6.9)	3.75 (0.77 to 18.13)	.08
Stroke-related death[d]	4/160 (2.5)	2/159 (1.3)			
Nonstroke-related death[d]	3/160 (1.9)	0/159 (0)			

Abbreviation: TIA, transient ischemic attack.

[a] One participant randomized to the medical therapy alone group was not included due to missing outcome data. See Figure 1.

[b] Adjusted for site effect.

[c] Log-rank test adjusted for site effect.

[d] Post hoc analysis.

[e] There were 5 ischemic stroke and 4 hemorrhagic strokes. Of the 4 symptomatic hemorrhagic strokes, 1 was periprocedural subarachnoid hemorrhage immediately after percutaneous transluminal angioplasty and stenting (probably related to guidewire perforation); 1 was periprocedural parenchymal and subdural brain hemorrhage evident immediately after percutaneous transluminal angioplasty and stenting (probably related to guidewire perforation); 1 was cerebellar and occipital hemorrhage that occurred 3 days after percutaneous transluminal angioplasty and stenting (probably related to reperfusion); and 1 was subarachnoid hemorrhage within 24 hours after percutaneous transluminal angioplasty and stenting (probably related to reperfusion). A total of 2 of these hemorrhages were fatal (1 developed massive cerebral infarction and brain hernia, and 1 had parenchymal brain hemorrhage), and 2 were nondisabling (1 cerebellar and occipital hemorrhage and 1 subarachnoid hemorrhage).

[f] There were 4 ischemic strokes and 0 hemorrhagic strokes. Of the 4 ischemic strokes, 2 were disabling, 2 were nondisabling, and none were fatal.

[g] One missing follow-up and 4 died.

[h] Four missing follow-up and 0 died.

[i] Four missing follow-up and 4 died.

[j] Eleven missing follow-up and 1 died.

[k] Eight missing follow-up, including 4 with primary outcomes (but no disabling stroke or death).

[l] Sixteen missing follow-up, including 5 with primary outcomes (but no disabling stroke or death).

[m] Four missing follow-up and 3 died.

[n] Ten missing follow-up and 0 died.

[o] Sixteen missing follow-up, including 12 with primary outcomes.

[p] The causes of death in the percutaneous transluminal angioplasty and stenting group were as follows: brain hemorrhage (n = 2), ischemic stroke (n = 2), sudden cardiac arrest (n = 1), intrahepatic cholangiocarcinoma (n = 1), and aortic artery aneurysm (n = 1).

[q] Twenty-three missing follow-up, including 12 with primary outcomes.

[r] The causes of death in the medical management group were as follows: ischemic stroke (n = 1) and brain hemorrhage (n = 1).

3. -

3-



No. at risk

Medical therapy alone group	182	170	166	162	159	151	151
Stenting group	176	163	162	155	152	149	149

The median time of observation was 36.0 months (IQR, 36.0-36.0) for the stenting group and 36.0 months (IQR, 36.0-36.0) for the medical therapy alone group. = .49 for log-rank testing between stenting group and medical therapy alone group with center as stratification factor.

h h ,
(T).

Discussion

Th , , -
h TIA h
h h h h -
h h , h
h , h
h h h h
h h .Th
h .
D h
, h h -
h h h h
h h -
h . Th h , h h
h , h A A -
N P A
h h ,
h h h h h h-
h .
C h , h
- h h h h
h h . Th -
h h h
h h h h
. Th h
h h - h. A
h h h

. O h -
h . Th
h SAMMPRIS
VISSIT. Th SAMMPRIS
VISSIT B h , h
Ch H .
Th - h hh h
h h SAMMPRIS VISSIT , -
h. I h , h -
h h h . h
h h
, h
. F , h h h-
- h -
h h . A -
h h- (> h)
h - h h(. %). Th -
hh h - -
h SAMMPRIS, h EAVE ,
h N I H h , h -
. D h h h h- . S ,
h A
h MRI -
h h , h h
h - - h -
. Th h
h h
. Th SAMMPRIS h . % -
h . A h
SAMMPRIS h h h
( ). Th ,
h h
. R h h
h h h Th
h
h (,),
h h h SAMMPRIS(
,) VISSIT(,). Ah h
h -
h / , h h -
h .
O h h h -
h h
. Th -
h h h h h
h h h (. % /
% / ; T S). I h ,
h h h h
h .I h -
, h h -
h h
h h h h -
h h h h h
. F h , -
(,
h)

Conclusions

A : June 27, 2022.

A A : Departments of Neurosurgery and Interventional Neuroradiology, Xuanwu Hospital, Capital Medical University, Beijing, China (Gao, T. Wang, Jiao); Department of Neurosurgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China (D. Wang); David Geffen School of Medicine, Department of Neurology and Comprehensive Stroke Center, University of California, Los Angeles (Liebeskind); Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, China (Shi, Zheng); Department of Cerebrovascular and Neurosurgery, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (Li); Department of Neurosurgery, Tangdu Hospital of Air Force Medical University, Xi'an, China (Zhao, Yu); Department of Neurology, Strategic Support Force Medical Center, Beijing, China (Cai); Department of Neurology, Qilu Hospital of Shandong University, Ji'nan, China (W. Wu); Department of Neurosurgery, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (He); Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China (H. Wang, Y. Wu); Neuroendovascular Program, Massachusetts General Hospital, Harvard Medical School, Boston (Dmytriw); Department of Medical Imaging, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada (Krings); Departments of Radiology and Neurology, University of Iowa Hospitals and Clinics, Iowa City (Derdeyn).

A C : Dr Jiao had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Gao, T. Wang, D. Wang, and Liebeskind are co-first authors.

C : Gao, T. Wang, D. Wang, Shi, Li, Zhao, Cai, W. Wu, He, Yu, Zheng, Dmytriw, Krings, Jiao.

A , , : All authors.

D : Gao, T. Wang, D. Wang, Shi, Li, Zhao, Cai, W. Wu, He, Yu, Zheng, Dmytriw, Jiao.

C : Gao, T. Wang, D. Wang, Liebeskind, H. Wang, Y. Wu, Dmytriw, Krings, Derdeyn, Jiao.

: H. Wang.

: Gao, Dmytriw, Jiao.

A , , : Gao, T. Wang, D. Wang, Liebeskind, Shi, Li, Zhao, Cai, W. Wu, He, Yu, Zheng, Jiao.

: Gao, Liebeskind, H. Wang, Krings, Jiao.

C D : Dr Liebeskind reported consultancy to the imaging core laboratories of Cerenovus, Genentech, Medtronic, Stryker, and Rapid Medical Inc during the conduct of the study. Dr Krings reported receiving personal fees from Stryker, Medtronic, Cerenovus, Penumbra, Stereotaxis, and Cranmed and royalties from Thieme and being a stockholder of Marblehead Inc outside the submitted work. Dr Derdeyn reported consultancy to Penumbra Inc, NoNO Inc, and Euphrates Vascular Inc. Dr Jiao reported receiving grants from the Ministry of Science and Technology of the People's Republic of China (2011BAI08B04) and Stryker Neurovascular during the conduct of the study, as well as grants from Ministry of Science and Technology of the People's Republic of China (SQ2016YFSF110141) outside the submitted work. No other disclosures were reported.

F / : This work was supported by a research grant (2011BAI08B04) from the National Health Commission of the People's Republic of China. Stryker Neurovascular provided supplemental funding for third-party site monitoring and auditing.

F / : The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**: The China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS) Trial Investigators are listed in Supplement 4.

**D : See Supplement 5.

**A C : We thank the patients and their families for participating in this trial.

1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. . 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0

2. Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. . 2019;394(10204):1145-1158. doi:10.1016/S0140-6736(19)30427-1

3. White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. *C* . 2005;111(10):1327-1331. doi:10.1161/01.CIR.0000157736.19739.D0

4. Wang Y, Zhao X, Liu L, et al; CICAS Study Group. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. . 2014;45(3):663-669. doi:10.1161/STROKEAHA.113.003508

5. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease. . 2008;39(8):2396-2399. doi:10.1161/STROKEAHA.107.505776

6. Arenillas JF. Intracranial atherosclerosis: current concepts. . 2011;42(1)(suppl):S20-S23.

7. Bose A, Hartmann M, Henkes H, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. . 2007;38(5):1531-1537. doi:10.1161/STROKEAHA.106.477711

8. Zaidat OO, Klucznik R, Alexander MJ, et al; NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. . 2008;70(17):1518-1524. doi:10.1212/01.wnl.0000306308.08229.a3

9. Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. . 2007;38(3):881-887. doi:10.1161/01.STR.0000257963.65728.e8

10. Kurre W, Berkefeld J, Brassel F, et al; INTRASTENT Study Group. In-hospital complication rates after stent treatment of 388 symptomatic intracranial stenoses. . 2010;41(3):494-498. doi:10.1161/STROKEAHA.109.568063

11. Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. *E* . 2011;365(11):993-1003. doi:10.1056/NEJMoa1105335

12. Zaidat OO, Fitzsimmons BF, Woodward BK, et al; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis. *A A*. 2015;313(12):1240-1248. doi:10.1001/jama.2015.1693

13. Miao Z, Jiang L, Wu H, et al. Randomized controlled trial of symptomatic middle cerebral artery stenosis. . 2012;43(12):3284-3290. doi:10.1161/STROKEAHA.112.662270

14. Miao Z, Zhang Y, Shuai J, et al; Study Group of Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China. Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China. . 2015;46(10):2822-2829. doi:10.1161/STROKEAHA.115.010549

15. Gao P, Wang D, Zhao Z, et al. Multicenter prospective trial of stent placement in patients with symptomatic high-grade intracranial stenosis. *A* . 2016;37(7):1275-1280. doi:10.3174/ajnr.A4698

16. Alexander MJ, Zauner A, Chaloupka JC, et al; WEAVE Trial Sites and Interventionalists. WEAVE trial. . 2019;50(4):889-894. doi:10.1161/STROKEAHA.118.023996

17. Gao P, Zhao Z, Wang D, et al. China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS). *I* . 2015;21(2):196-204. doi:10.1177/1591019915581778

18. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized method for measuring intracranial arterial stenosis. *A A* . 2000;21(4):643-646.

19. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *E* . 2005;352(13):1305-1316. doi:10.1056/NEJMoa043033

20. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. . 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024

21. Jiang WJ, Yu W, Du B, Gao F, Cui LY. Outcome of patients with ≥70% symptomatic intracranial stenosis after Wingspan stenting. . 2011;42(7):1971-1975. doi:10.1161/STROKEAHA.110.595926

22. Tang CW, Chang FC, Chern CM, Lee YC, Hu HH, Lee IH. Stenting versus medical treatment for severe symptomatic intracranial stenosis. *A A* . 2011;32(5):911-916. doi:10.3174/ajnr.A2409

23. Turan TN, Zaidat OO, Gronseth GS, et al. Stroke prevention in symptomatic large artery intracranial atherosclerosis practice advisory. . 2022;98(12):486-498. doi:10.1212/WNL.0000000000200030

24. Derdeyn CP, Fiorella D, Lynn MJ, et al; SAMMPRIS Trial Investigators. Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. . 2013;5(6):528-533. doi:10.1136/neurintsurg-2012-010504

25. Nahab F, Lynn MJ, Kasner SE, et al; NIH Multicenter Wingspan Intracranial Stent Registry Study Group. Risk factors associated with major cerebrovascular complications after intracranial stenting. . 2009;72(23):2014-2019. doi:10.1212/01.wnl.0b013e3181a1863c

26. Yu SC, Leung TW, Lee KT, Wong LK. Learning curve of Wingspan stenting for intracranial atherosclerosis. . 2014;6(3):212-218. doi:10.1136/neurintsurg-2012-010593

27. Wabnitz AM, Derdeyn CP, Fiorella DJ, et al; SAMMPRIS Investigators. Hemodynamic markers in the anterior circulation as predictors of recurrent stroke in patients with intracranial stenosis. . Published December 11, 2018. doi:10.1161/STROKEAHA.118.020840

28. Derdeyn CP, Fiorella D, Lynn MJ, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Mechanisms of stroke after intracranial angioplasty and stenting in the SAMMPRIS trial. . 2013;72(5):777-795. doi:10.1227/NEU.0b013e318286fdc8

29. Abou-Chebl A. Intracranial stenting with Wingspan: still awaiting a safe landing. . 2011;42(7):1809-1811. doi:10.1161/STROKEAHA.111.620229

30. Zhang Y, Sun Y, Li X, et al. Early versus delayed stenting for intracranial atherosclerotic artery stenosis with ischemic stroke. . 2020;12(3):274-278. doi:10.1136/neurintsurg-2019-015035

31. Yu Y, Wang T, Yang K, et al. Timing and outcomes of intracranial stenting in the post-SAMMPRIS era. *F* . 2021;12:637632. doi:10.3389/fneur.2021.637632

32. Wang T, Luo J, Wang X, et al. Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis. . 2021;52(2):e53-e54. doi:10.1161/STROKEAHA.120.032988

33. Derdeyn CP, Chimowitz MI, Lynn MJ, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS). . 2014;383(9914):333-341. doi:10.1016/S0140-6736(13)62038-3

34. Romano JG, Prabhakaran S, Nizam A, et al; MyRIAD Investigators. Infarct recurrence in intracranial atherosclerosis. *C D* . 2021;30(2):105504. doi:10.1016/j.jstrokecerebrovasdis.2020.105504

35. Dumont TM, Sonig A, Mokin M, et al. Submaximal angioplasty for symptomatic intracranial atherosclerosis. . 2016;125(4):964-971. doi:10.3171/2015.8.JNS15791

36. Remonda L, Diepers M, Berberat J, et al. Drug-coated balloon treatment in symptomatic intracranial high grade stenosis. *C* . 2021;31(1):45-49. doi:10.1007/s00062-020-00936-9

37. Jia B, Zhang X, Ma N, et al; NOVA Trial Investigators. Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis. *A A* . 2022;79(2):176-184. doi:10.1001/jamaneurol.2021.4804

38. Zhang J, Zhang X, Zhang J, et al. Drug-coated balloon dilation compared with conventional stenting angioplasty for intracranial atherosclerotic disease. . 2020;87(5):992-998. doi:10.1093/neuros/nyaa191